Supplemental Table 2A

I.D.	Treatment	Dose	Total Reads	#1-Indel (W/T)	#1-Reads(%)	#2-Indel	#2-Reads(%)	#3-Indel	#3-Reads(%)	#4-Indel	#4-Reads(%)	#5-Indel	#5-Reads(%)	#6-Indel	#6-Reads(%)	#7-Indel	#7-Reads(%)	#8-Indel	#8-Reads(%)
1	PBS	0 VP/Cell	238	0	237 (99.6%)	-1	1 (0.4%)	NA											
2	PBS	0 VP/Cell	388	0	387 (99.7%)	-3	1 (0.3%)	NA											
3	Ad5-Cas9-gRNA	1 x 10 ³ VP/cell	318	0	309 (97.2%)	-1	5 (1.6%)	-15	2 (0.6%)	-118	1 (0.3%)	-68	1 (0.3%)	NA		NA		NA	
4	Ad5-Cas9-gRNA	1 x 10 ³ VP/cell	453	0	438 (96.7%)	-1	6 (1.3%)	-3	2 (0.4%)	-19	1 (0.2%)	-17	1 (0.2%)	-15	1 (0.2%)	-2	1 (0.2%)	-41	1 (0.2%)
5	Ad5-Cas9-gRNA	2 x 10 ³ VP/cell	362	0	343 (94.8%)	-15	3 (0.8%)	-125	2 (0.6%)	-14	2 (0.6%)	-3	2 (0.6%)	-1	2 (0.6%)	-28	1 (0.3%)	-91	1 (0.3%)
6	Ad5-Cas9-gRNA	2 x 10 ³ VP/cell	339	0	322 (95.0%)	-15	4 (1.2%)	-1	3 (0.9%)	-2	2 (0.6%)	-3	2 (0.6%)	-112	1 (0.3%)	-54	1 (0.3%)	-16	1 (0.3%)
7	Ad5-Cas9-gRNA	4 x 10 ³ VP/cell	439	0	417 (95.0%)	-15	5 (1.1%)	-1	4 (0.9%)	-74	3 (0.7%)	-2	3 (0.7%)	-12	2 (0.5%)	-95	1 (0.2%)	-27	1 (0.2%)
8	Ad5-Cas9-gRNA	4 x 10 ³ VP/cell	537	0	480 (89.4%)	-15	16 (3.0%)	-1	8 (1.5%)	-2	4 (0.7%)	-19	3 (0.6%)	-108	2 (0.4%)	-80	2 (0.4%)	-43	2 (0.4%)
9	Ad5-Cas9-gRNA	6 x 10 ³ VP/cell	361	0	301 (83.4%)	-15	16 (4.4%)	-1	11 (3.0%)	-2	5 (1.4%)	-3	4 (1.1%)	-80	2 (0.6%)	-79	2 (0.6%)	-19	2 (0.6%)
10	Ad5-Cas9-gRNA	6 x 10 ³ VP/cell	281	0	226 (80.4%)	-15	12 (4.3%)	-1	9 (3.2%)	-2	4 (1.4%)	-3	3 (1.1%)	1	2 (0.7%)	-79	2 (0.7%)	-43	2 (0.7%)
11	Ad5-Cas9-gRNA	8 x 10 ³ VP/cell	501	0	390 (77.8%)	-1	24 (4.8%)	-15	16 (3.2%)	-2	10 (2.0%)	-3	8 (1.6%)	1	7 (1.4%)	-26	4 (0.8%)	-95	3 (0.6%)
12	Ad5-Cas9-gRNA	8 x 10 ³ VP/cell	388	0	310 (79.9%)	-15	13 (3.4%)	-1	12 (3.1%)	1	4 (1.0%)	-116	3 (0.8%)	-114	3 (0.8%)	-16	3 (0.8%)	-2	3 (0.8%)
13	Ad5-Cas9-gRNA	1 x 10 ⁴ VP/cell	350	0	255 (72.9%)	-15	17 (4.9%)	-2	14 (4.0%)	-1	12 (3.4%)	1	6 (1.7%)	-3	5 (1.4%)	-19	4 (1.1%)	-66	3 (0.9%)
14	Ad5-Cas9-gRNA	1 x 10 ⁴ VP/cell	211	0	156 (73.9%)	-15	9 (4.3%)	-1	9 (4.3%)	-3	6 (2.8%)	1	3 (1.4%)	-2	3 (1.4%)	-80	2 (0.9%)	-23	2 (0.9%)
15	Ad5-Cas9-gRNA	2 x 10 ⁴ VP/cell	346	0	184 (53.2%)	-1	35 (10.1%)	-15	22 (6.4%)	-2	15 (4.3%)	-3	9 (2.6%)	-19	5 (1.4%)	-79	4 (1.2%)	1	3 (0.9%)
16	Ad5-Cas9-gRNA	2 x 10 ⁴ VP/cell	462	0	271 (58.7%)	-1	35 (7.6%)	-15	32 (6.9%)	-2	24 (5.2%)	-3	17 (3.7%)	-35	5 (1.1%)	-19	5 (1.1%)	-22	4 (0.9%)

Supplemental Table 2B

I.D.	Treatment	Dose	Total Reads	#1-Indel (W/T)	#1-Reads(%)	#2-Indel	#2-Reads(%)	#3-Indel	#3-Reads(%)	#4-Indel	#4-Reads(%)	#5-Indel	#5-Reads(%)	#6-Indel	#6-Reads(%)	#7-Indel	#7-Reads(%)	#8-Indel	#8-Reads(%)
2	PBS	0 VP	578	0	567 (98.1%)	-1	10 (1.7%)	-2	1 (0.2%)	NA									
3	Ad5-EF1a-eGFP + Ad5-gRNA	5 x 10 ¹⁰ VP (each vector)	3629	0	3556 (98.0%)	-1	63 (1.7%)	-2	9 (0.2%)	1	1 (0.0%)	NA		NA		NA		NA	
4	Ad5-EF1α-eGFP + Ad5-gRNA	5 x 10 ¹⁰ VP (each vector)	3486	0	3422 (98.2%)	-1	52 (1.5%)	46	6 (0.2%)	-2	3 (0.1%)	1	2 (0.1%)	2	1 (0.0%)	NA		NA	
5	Ad5-EF1α-eGFP + Ad5-gRNA	5 x 10 ¹⁰ VP (each vector)	4269	0	4169 (97.7%)	-1	89 (2.1%)	-2	7 (0.2%)	1	4 (0.1%)	NA		NA		NA		NA	
6	Ad5-EF1α-eGFP + Ad5-gRNA	5 x 10 ¹⁰ VP (each vector)	539	0	526 (97.6%)	-1	12 (2.2%)	-2	1 (0.2%)	NA									
7	Ad5-EF1α-eGFP + Ad5-Cas9-gRNA	5 x 10 ¹⁰ VP (each vector)	3649	0	3473 (95.2%)	-1	88 (2.4%)	46	21 (0.6%)	-2	20 (0.5%)	1	12 (0.3%)	-15	3 (0.1%)	-3	3 (0.1%)	2	2 (0.1%)
9	Ad5-EF1α-eGFP + Ad5-Cas9-gRNA	5 x 10 ¹⁰ VP (each vector)	3460	0	3273 (94.6%)	-1	88 (2.5%)	1	17 (0.5%)	-2	16 (0.5%)	-3	8 (0.2%)	-19	4 (0.1%)	-15	4 (0.1%)	-120	3 (0.1%)
10	Ad5-EF1α-eGFP + Ad5-Cas9-gRNA	5 x 10 ¹⁰ VP (each vector)	3249	0	3091 (95.1%)	-1	75 (2.3%)	-2	20 (0.6%)	-3	15 (0.5%)	1	9 (0.3%)	-15	5 (0.2%)	-34	3 (0.1%)	-11	2 (0.1%)
11	Ad5-EF1α-eGFP + Ad5-Cas9-gRNA	5 x 10 ¹⁰ VP (each vector)	5431	0	5212 (96.0%)	-1	122 (2.2%)	-2	27 (0.5%)	1	14 (0.3%)	-3	6 (0.1%)	-15	4 (0.1%)	-103	3 (0.1%)	-66	3 (0.1%)
12	Ad5-EF1α-eGFP + Ad5-Cas9-gRNA	5 x 10 ¹⁰ VP (each vector)	3649	0	3471 (95.1%)	-1	86 (2.4%)	-2	30 (0.8%)	-3	9 (0.2%)	1	8 (0.2%)	-15	6 (0.2%)	-4	5 (0.1%)	-5	3 (0.1%)
13	Ad5-EF1α-eGFP + Ad5-Cas9-gRNA	5 x 10 ¹⁰ VP (each vector)	4509	0	4095 (90.8%)	-1	138 (3.1%)	-2	47 (1.0%)	1	35 (0.8%)	-15	23 (0.5%)	-3	23 (0.5%)	-4	10 (0.2%)	2	9 (0.2%)
14	Ad5-EF1α-eGFP + Ad5-Cas9-gRNA	5 x 10 ¹⁰ VP (each vector)	1026	0	919 (89.6%)	-1	43 (4.2%)	1	9 (0.9%)	-15	9 (0.9%)	-2	9 (0.9%)	-3	7 (0.7%)	-18	4 (0.4%)	-27	3 (0.3%)
15	Ad5-EF1α-eGFP + Ad5-Cas9-gRNA	5 x 10 ¹⁰ VP (each vector)	3515	0	3349 (95.3%)	-1	84 (2.4%)	-2	16 (0.5%)	1	10 (0.3%)	-15	7 (0.2%)	-4	4 (0.1%)	-3	4 (0.1%)	46	3 (0.1%)